Headquartered in Andover, MA Fiscal year ends December NASDAQ: TMDX transmedics.com
TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The company developed the Organ Care System (OCS), a portable extracorporeal warm perfusion and assessment platform designed to preserve organ quality, assess organ viability prior to transplant, and increase utilization of donor organs. TransMedics operates the National OCS Program (NOP), an integrated logistics and clinical service platform that pairs OCS technology with dedicated transportation and clinical support to expand access to organ transplantation. The company generates revenue from two streams: net product revenue from OCS disposables and devices, and service revenue from its logistics and clinical services operations. TransMedics is actively expanding internationally, including through its strategic investment in PAD Aviation to build a dedicated organ transplant air logistics network in Europe. The company is also advancing its pipeline, including OCS Kidney and Gen 3.0 technology, along with the ENHANCE Part B and DENOVO clinical trials. Updated
Live Updates Final take on tonight's earnings 5:26pm ETPost-Earnings Move: 🟢 +6.48% What Happened:Revenue of $157.4M beat by ~7% and EPS of $0.92 more than doubled the $0.43 consensus. Net income jumped…
Eric Bleeker In 2024, the fastest-growing stocks have been in the momentum category, led by NVIDIA (NASDAQ: NVDA) | NVDA Price Prediction. We reviewed the sales growth rates of some of the other fastest-growing…
TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure.
The Wall Street consensus 12-month price target for TMDX is $97.80.